Back to Forecasting
WVE Forecast Markets
Wave Life Sciences Ltd.
7
Active Markets
44%
Avg Probability
All Markets
7 markets
Will WVE-007 Phase IIa 6-month data show total body weight loss of 5% or greater in the 240mg cohort?
36%
Likely No
92% agreement
Jun 30, 2026
IG: 0.80
Will FDA indicate willingness to accept biomarker endpoints for WVE-006 accelerated approval by mid-2026?
36%
Likely No
95% agreement
Sep 30, 2026
IG: 0.80
Will Wave Life Sciences maintain cash and equivalents above $400M at Q3 2026 quarter-end?
59%
Likely Yes
96% agreement
Nov 15, 2026
IG: 0.64
Will GSK select a 5th program under the Wave Life Sciences collaboration by year-end 2026?
60%
Likely Yes
94% agreement
Dec 31, 2026
IG: 0.64
Will Wave Life Sciences announce an equity offering or ATM program before key Q2 2026 clinical data readouts?
24%
Likely No
94% agreement
Jun 30, 2026
IG: 0.64
Will Wave Life Sciences keep quarterly R&D expenses below $60M for all quarters of FY2026?
35%
Likely No
92% agreement
Mar 15, 2027
IG: 0.48
Will Wave Life Sciences submit an NDA for WVE-N531 (DMD) to the FDA by year-end 2026?
57%
Likely Yes
93% agreement
Dec 31, 2026
IG: 0.48
Resolution Timeline
Jun 30, 2026
Will WVE-007 Phase IIa 6-month data show total body weight loss of 5% or greater in the 240mg cohort?Prediction: 36%
Sep 30, 2026
Will FDA indicate willingness to accept biomarker endpoints for WVE-006 accelerated approval by mid-2026?Prediction: 36%
Nov 15, 2026
Will Wave Life Sciences maintain cash and equivalents above $400M at Q3 2026 quarter-end?Prediction: 59%
Dec 31, 2026
Will GSK select a 5th program under the Wave Life Sciences collaboration by year-end 2026?Prediction: 60%
Dec 31, 2026
Will Wave Life Sciences submit an NDA for WVE-N531 (DMD) to the FDA by year-end 2026?Prediction: 57%
Mar 15, 2027
Will Wave Life Sciences keep quarterly R&D expenses below $60M for all quarters of FY2026?Prediction: 35%